Preclinical research into the novel compound R805/CX-011’s effect on glycoprotein 130 (gp130) has shown that the agent may decrease hyperinflammation associated with the receptor. This early research was published by Shkyan et al in Science Translational Medicine. In mouse models, researchers “saw a profound effect on joint pain, structure, and function” in animals treated with R805/CX-011, said senior study author Denis Evseenko, MD, PhD, a Professor of Orthopaedic Surgery, Stem Cell Research, and Regenerative Medicine at the Keck School of Medicine of USC, in a companion press release on the findings. Based on the preclinical findings, a phase I/IIa combined safety and preliminary efficacy trial of R805/CX-011 will launch later this year, funded by the Department of Defense and planned to include 70 patients with knee osteoarthritis.
May 25, 2023